Cargando…
Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
BACKGROUND AND AIMS: Lerodalcibep, a novel small recombinant fusion protein of a proprotein convertase subtilisin/kexin type 9 gene–binding domain (adnectin) and human serum albumin, demonstrated highly effective low-density lipoprotein cholesterol (LDL-C) reduction with monthly 300 mg in 1.2 mL sub...
Autores principales: | Raal, Frederick, Fourie, Nyda, Scott, Russell, Blom, Dirk, De Vries Basson, Matthys, Kayikcioglu, Meral, Caldwell, Kate, Kallend, David, Stein, Evan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590131/ https://www.ncbi.nlm.nih.gov/pubmed/37639462 http://dx.doi.org/10.1093/eurheartj/ehad596 |
Ejemplares similares
-
E670G PCSK9 polymorphism in HeFH & CAD with diabetes: is the bridge to personalized therapy within reach?
por: Alieva, Rano, et al.
Publicado: (2023) -
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015) -
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022) -
Anisotropic Isolation by Distance: The Main Orientations of Human Genetic Differentiation
por: Jay, Flora, et al.
Publicado: (2013) -
Good Codons, Bad Transcript: Large Reductions in Gene Expression and Fitness Arising from Synonymous Mutations in a Key Enzyme
por: Agashe, Deepa, et al.
Publicado: (2013)